Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083.

2.

High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.

Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Snaebjornsson P, Kuipers EJ, Bruno MJ, Dekker E, Meijer GA, de Boer JP, van Leeuwen FE, van Leerdam ME.

Cancer. 2018 Dec 18. doi: 10.1002/cncr.31903. [Epub ahead of print]

PMID:
30561773
3.

Molecular profiling of longitudinally observed small colorectal polyps: A cohort study.

van Lanschot MCJ, Carvalho B, Rausch C, Snaebjornsson P, van Engeland M, Kuipers EJ, Stoker J, Tutein Nolthenius CJ, Dekker E, Meijer GA.

EBioMedicine. 2019 Jan;39:292-300. doi: 10.1016/j.ebiom.2018.12.009. Epub 2018 Dec 13.

4.

Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer.

Neerincx M, Poel D, Sie DLS, van Grieken NCT, Shankaraiah RC, van der Wolf-de Lijster FSW, van Waesberghe JTM, Burggraaf JD, Eijk PP, Verhoef C, Ylstra B, Meijer GA, van de Wiel MA, Buffart TE, Verheul HMW.

PLoS One. 2018 Aug 3;13(8):e0201809. doi: 10.1371/journal.pone.0201809. eCollection 2018.

5.

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

van den Broek E, den Uil SH, Coupé VMH, Delis-van Diemen PM, Bolijn AS, Bril H, Stockmann HBAC, van Grieken NCT, Meijer GA, Fijneman RJA.

Oncotarget. 2018 Jun 29;9(50):29445-29452. doi: 10.18632/oncotarget.25655. eCollection 2018 Jun 29.

6.

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.

Labots M, Van der Mijn JC, Dekker H, Ruijter R, Pham TV, Van der Vliet HJ, Van der Hoeven JJM, Meijer GA, Verheul HMW.

Oncologist. 2018 Oct;23(10):1135-e118. doi: 10.1634/theoncologist.2018-0263. Epub 2018 Jul 17.

7.

Consensus molecular subtype classification of colorectal adenomas.

Komor MA, Bosch LJ, Bounova G, Bolijn AS, Delis-van Diemen PM, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, van Grieken NC, Carvalho B, Wessels LF, Jimenez CR, Fijneman RJ, Meijer GA; NGS-ProToCol Consortium:.

J Pathol. 2018 Nov;246(3):266-276. doi: 10.1002/path.5129. Epub 2018 Aug 31.

8.

World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer.

Rutter MD, Beintaris I, Valori R, Chiu HM, Corley DA, Cuatrecasas M, Dekker E, Forsberg A, Gore-Booth J, Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Plumb AA, Rabeneck L, Robertson DJ, Schoen RE, Singh H, Tinmouth J, Young GP, Sanduleanu S.

Gastroenterology. 2018 Sep;155(3):909-925.e3. doi: 10.1053/j.gastro.2018.05.038. Epub 2018 Jun 27.

PMID:
29958856
9.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
10.

Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer.

Jacobsen A, Bosch LJW, Martens-de Kemp SR, Carvalho B, Sillars-Hardebol AH, Dobson RJ, de Rinaldis E, Meijer GA, Abeln S, Heringa J, Fijneman RJA, Feenstra KA.

Sci Rep. 2018 May 14;8(1):7522. doi: 10.1038/s41598-018-24982-z.

11.

Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas.

Carvalho B, Diosdado B, Terhaar Sive Droste JS, Bolijn AS, Komor MA, de Wit M, Bosch LJW, van Burink M, Dekker E, Kuipers EJ, Coupé VMH, van Grieken NCT, Fijneman RJA, Meijer GA.

Cancer Prev Res (Phila). 2018 Jul;11(7):403-412. doi: 10.1158/1940-6207.CAPR-17-0317. Epub 2018 Apr 23.

PMID:
29685877
12.

[National population screening for colorectal carcinoma in the Netherlands: results of the first years since the implementation in 2014].

Elferink MAG, Toes-Zoutendijk E, Vink GR, Lansdorp-Vogelaar I, Meijer GA, Dekker E, Lemmens VEPP.

Ned Tijdschr Geneeskd. 2018;162:D2283. Dutch.

PMID:
29519262
13.

Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.

Rigter LS, Snaebjornsson P, Rosenberg EH, Atmodimedjo PN, Aleman BM, Ten Hoeve J, Geurts-Giele WR; PALGA group, van Ravesteyn TW, Hoeksel J, Meijer GA, Te Riele H, van Leeuwen FE, Dinjens WN, van Leerdam ME.

Gut. 2018 Mar;67(3):447-455. doi: 10.1136/gutjnl-2016-312608. Epub 2016 Nov 8.

PMID:
29439113
14.

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.

Bosch LJW, de Wit M, Pham TV, Coupé VMH, Hiemstra AC, Piersma SR, Oudgenoeg G, Scheffer GL, Mongera S, Sive Droste JT, Oort FA, van Turenhout ST, Larbi IB, Louwagie J, van Criekinge W, van der Hulst RWM, Mulder CJJ, Carvalho B, Fijneman RJA, Jimenez CR, Meijer GA.

Ann Intern Med. 2017 Dec 19;167(12):855-866. doi: 10.7326/M17-1068. Epub 2017 Nov 21.

PMID:
29159365
15.

Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.

Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupé VMH.

Ann Intern Med. 2017 Oct 17;167(8):544-554. doi: 10.7326/M16-2891. Epub 2017 Oct 3.

PMID:
28973514
16.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

17.

Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify.

Komor MA, Pham TV, Hiemstra AC, Piersma SR, Bolijn AS, Schelfhorst T, Delis-van Diemen PM, Tijssen M, Sebra RP, Ashby M, Meijer GA, Jimenez CR, Fijneman RJA.

Mol Cell Proteomics. 2017 Oct;16(10):1850-1863. doi: 10.1074/mcp.TIR117.000056. Epub 2017 Jul 26.

18.

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):504-512.e11. doi: 10.1016/j.cgh.2017.07.011. Epub 2017 Jul 18.

PMID:
28733262
19.

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, van Laarhoven HWM; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group.

Acta Oncol. 2018 Feb;57(2):195-202. doi: 10.1080/0284186X.2017.1346381. Epub 2017 Jul 19.

PMID:
28723307
20.

GeneBreak: detection of recurrent DNA copy number aberration-associated chromosomal breakpoints within genes.

van den Broek E, van Lieshout S, Rausch C, Ylstra B, van de Wiel MA, Meijer GA, Fijneman RJA, Abeln S.

Version 2. F1000Res. 2016 Sep 19 [revised 2017 Jan 1];5:2340. doi: 10.12688/f1000research.9259.2. eCollection 2016.

21.

Early detection: the impact of genomics.

van Lanschot MCJ, Bosch LJW, de Wit M, Carvalho B, Meijer GA.

Virchows Arch. 2017 Aug;471(2):165-173. doi: 10.1007/s00428-017-2159-2. Epub 2017 Jun 1. Review.

PMID:
28573511
22.

Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.

de Wit M, Carvalho B, Delis-van Diemen PM, van Alphen C, Beliën JAM, Meijer GA, Fijneman RJA.

PLoS One. 2017 May 8;12(5):e0174768. doi: 10.1371/journal.pone.0174768. eCollection 2017.

23.

Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years.

Snaebjornsson P, Jonasson L, Olafsdottir EJ, van Grieken NCT, Moller PH, Theodors A, Jonsson T, Meijer GA, Jonasson JG.

Int J Cancer. 2017 Aug 1;141(3):531-539. doi: 10.1002/ijc.30766. Epub 2017 May 19.

24.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJA, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2017 Jun 15;36(24):3504. doi: 10.1038/onc.2017.3. Epub 2017 Feb 13.

PMID:
28192405
25.

Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.

van Lanschot MC, Carvalho B, Coupé VM, van Engeland M, Dekker E, Meijer GA.

BMC Cancer. 2017 Feb 7;17(1):116. doi: 10.1186/s12885-017-3078-y.

26.

Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roesink JM, Raemaekers JM, van der Maazen RW, Cats A, Bleiker EM, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, Te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME.

BMC Cancer. 2017 Feb 7;17(1):112. doi: 10.1186/s12885-017-3089-8.

27.

Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.

Toes-Zoutendijk E, van Leerdam ME, Dekker E, van Hees F, Penning C, Nagtegaal I, van der Meulen MP, van Vuuren AJ, Kuipers EJ, Bonfrer JMG, Biermann K, Thomeer MGJ, van Veldhuizen H, Kroep S, van Ballegooijen M, Meijer GA, de Koning HJ, Spaander MCW, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group.

Gastroenterology. 2017 Mar;152(4):767-775.e2. doi: 10.1053/j.gastro.2016.11.022. Epub 2016 Nov 24.

PMID:
27890769
28.

Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

den Uil SH, Coupé VM, Linnekamp JF, van den Broek E, Goos JA, Delis-van Diemen PM, Belt EJ, van Grieken NC, Scott PM, Vermeulen L, Medema JP, Bril H, Stockmann HB, Cormier RT, Meijer GA, Fijneman RJ.

Br J Cancer. 2016 Dec 6;115(12):1565-1574. doi: 10.1038/bjc.2016.376. Epub 2016 Nov 17.

29.

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.

van den Broek E, Krijgsman O, Sie D, Tijssen M, Mongera S, van de Wiel MA, Belt EJ, den Uil SH, Bril H, Stockmann HB, Ylstra B, Carvalho B, Meijer GA, Fijneman RJ.

Oncotarget. 2016 Nov 8;7(45):73876-73887. doi: 10.18632/oncotarget.12510.

30.

Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research.

Burbach JP, Kurk SA, Coebergh van den Braak RR, Dik VK, May AM, Meijer GA, Punt CJ, Vink GR, Los M, Hoogerbrugge N, Huijgens PC, Ijzermans JN, Kuipers EJ, de Noo ME, Pennings JP, van der Velden AM, Verhoef C, Siersema PD, van Oijen MG, Verkooijen HM, Koopman M.

Acta Oncol. 2016 Nov;55(11):1273-1280. Epub 2016 Aug 25.

PMID:
27560599
31.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

van der Meijde E, van den Eertwegh AJ, Linn SC, Meijer GA, Fijneman RJ, Coupé VM.

Cancer Inform. 2016 Jun 15;15:115-27. doi: 10.4137/CIN.S38122. eCollection 2016.

32.

Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.

Obulkasim A, Ylstra B, van Essen HF, Benner C, Stenning S, Langley R, Allum W, Cunningham D, Inam I, Hewitt LC, West NP, Meijer GA, van de Wiel MA, Grabsch HI.

Oncotarget. 2016 Jul 12;7(28):44084-44095. doi: 10.18632/oncotarget.9857.

33.

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, Stoker J, Coupé VM.

Br J Radiol. 2016 Jul;89(1063):20150910. doi: 10.1259/bjr.20150910. Epub 2016 May 19.

34.

WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.

Bosch LJ, Luo Y, Lao VV, Snaebjornsson P, Trooskens G, Vlassenbroeck I, Mongera S, Tang W, Welcsh P, Herman JG, Koopman M, Nagtegaal ID, Punt CJ, van Criekinge W, Meijer GA, Monnat RJ Jr, Carvalho B, Grady WM.

Clin Cancer Res. 2016 Sep 15;22(18):4612-22. doi: 10.1158/1078-0432.CCR-15-2703. Epub 2016 Apr 27.

35.

Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Sluiter NR, de Cuba EM, Kwakman R, Meijerink WJ, Delis-van Diemen PM, Coupé VM, Beliën JA, Meijer GA, de Hingh IH, te Velde EA.

Clin Exp Metastasis. 2016 Apr;33(4):297-307. doi: 10.1007/s10585-016-9779-9. Epub 2016 Feb 12.

36.

Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer.

Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt PM, Silva MD, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJ, Sung JJ, Winawer SJ.

Cancer. 2016 Mar 15;122(6):826-39. doi: 10.1002/cncr.29865. Epub 2016 Feb 1.

37.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2016 Aug 11;35(32):4179-87. doi: 10.1038/onc.2015.483. Epub 2016 Jan 11. Erratum in: Oncogene. 2017 Jun 15;36(24):3504.

38.

Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.

de Cuba EM, de Hingh IH, Sluiter NR, Kwakman R, Coupé VM, Beliën JA, Verwaal VJ, Meijerink WJ, Delis-van Diemen PM, Bonjer HJ, Meijer GA, Te Velde EA.

Ann Surg Oncol. 2016 May;23(5):1601-8. doi: 10.1245/s10434-015-5023-0. Epub 2016 Jan 4.

39.

Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis.

IJspeert JE, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, Sanduleanu S, Bisseling TM, Spaander MC, Clark SK, Meijer GA, van Lelyveld N, Koornstra JJ, Nagtegaal ID, East JE, Latchford A, Dekker E; Dutch workgroup serrated polyps & polyposis (WASP).

Gut. 2017 Feb;66(2):278-284. doi: 10.1136/gutjnl-2015-310630. Epub 2015 Nov 24.

40.

Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway.

Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, Dekker E, Meijer GA, Coupé VM.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):135-44. doi: 10.1158/1055-9965.EPI-15-0592. Epub 2015 Nov 23.

41.

A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.

Goos JA, Coupé VM, van de Wiel MA, Diosdado B, Delis-Van Diemen PM, Hiemstra AC, de Cuba EM, Beliën JA, Menke-van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ; DeCoDe PET Group.

Oncotarget. 2016 Jan 12;7(2):2123-34. doi: 10.18632/oncotarget.6188.

42.

MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing.

Neerincx M, Sie DL, van de Wiel MA, van Grieken NC, Burggraaf JD, Dekker H, Eijk PP, Ylstra B, Verhoef C, Meijer GA, Buffart TE, Verheul HM.

Oncogenesis. 2015 Oct 5;4:e170. doi: 10.1038/oncsis.2015.29.

43.

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).

Goos JACM, Verbeek J, Geldof AA, Hiemstra AC, van de Wiel MA, Adamzek KA, Delis-Van Diemen PM, Stroud SG, Bradley DP, Meijer GA, Hoekstra OS, Fijneman RJA, Windhorst AD.

Nucl Med Biol. 2016 Jan;43(1):63-72. doi: 10.1016/j.nucmedbio.2015.08.007. Epub 2015 Sep 11.

PMID:
26432753
44.

Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.

Turksma AW, Coupé VM, Shamier MC, Lam KL, de Weger VA, Belien JA, van den Eertwegh AJ, Meijer GA, Meijer CJ, Hooijberg E.

Clin Cancer Res. 2016 Jan 15;22(2):346-56. doi: 10.1158/1078-0432.CCR-13-2462. Epub 2015 Sep 29.

45.

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, Belt E, Bril H, Stockmann HB, Hooijberg E, Punt CJ, Koopman M, Nagtegaal ID, Coupé VH, Carvalho B, Meijer GA.

Int J Cancer. 2016 Mar 1;138(5):1139-45. doi: 10.1002/ijc.29855. Epub 2015 Oct 23.

46.

High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.

van den Broek E, Dijkstra MJ, Krijgsman O, Sie D, Haan JC, Traets JJ, van de Wiel MA, Nagtegaal ID, Punt CJ, Carvalho B, Ylstra B, Abeln S, Meijer GA, Fijneman RJ.

PLoS One. 2015 Sep 16;10(9):e0138141. doi: 10.1371/journal.pone.0138141. eCollection 2015.

47.

Reduced rate of copy number aberrations in mucinous colorectal carcinoma.

Hugen N, Simmer F, Mekenkamp LJ, Koopman M, van den Broek E, de Wilt JH, Punt CJ, Ylstra B, Meijer GA, Nagtegaal ID.

Oncotarget. 2015 Sep 22;6(28):25715-25. doi: 10.18632/oncotarget.4706.

48.

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

Lenos K, Goos JA, Vuist IM, den Uil SH, Delis-van Diemen PM, Belt EJ, Stockmann HB, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJ, van Vliet SJ.

Oncotarget. 2015 Sep 22;6(28):26278-90. doi: 10.18632/oncotarget.4495.

49.

Oncogenic Role of miR-15a-3p in 13q Amplicon-Driven Colorectal Adenoma-to-Carcinoma Progression.

de Groen FL, Timmer LM, Menezes RX, Diosdado B, Hooijberg E, Meijer GA, Steenbergen RD, Carvalho B.

PLoS One. 2015 Jul 6;10(7):e0132495. doi: 10.1371/journal.pone.0132495. eCollection 2015.

50.

Serrated neoplasia-role in colorectal carcinogenesis and clinical implications.

IJspeert JE, Vermeulen L, Meijer GA, Dekker E.

Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):401-9. doi: 10.1038/nrgastro.2015.73. Epub 2015 May 12. Review.

PMID:
25963511

Supplemental Content

Loading ...
Support Center